DDInter103 DDInter1676
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types. Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Antilymphocyte immunoglobulin (horse) {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Antilymphocyte immunoglobulin (horse) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Antilymphocyte immunoglobulin (horse) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Antilymphocyte immunoglobulin (horse) {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Antilymphocyte immunoglobulin (horse) {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Cladribine